Leerink Raises Price Target as Roivant (ROIV) Accelerates Drug Development Pipeline
Roivant Sciences Ltd. (NASDAQ:ROIV) ranks among the best stocks under $25 to buy now.
Roivant Sciences Ltd. (ROIV)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | QVT Financial Daniel Gold | 29,381,635 | $444,544,138 | 31.37% | |
| 2. | Viking Global Andreas Halvorsen | 23,594,831 | $356,989,793 | -32% | 0.93% |
| 3. | Rubric Capital Management David Rosen | 20,000,000 | $302,600,000 | -2% | 3.41% |
| 4. | Two Seas Capital Sina Toussi | 11,754,164 | $177,840,501 | +11% | 2.85% |
| 5. | Perceptive Advisors Joseph Edelman | 7,368,461 | $111,484,815 | +122% | 3.22% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $15.07 | 3,315 | $49,957.05 | 17,287,081 | 2025-09-18 | Filing | |
| $5.00 | 4,000,000 | $20,000,000.00 | 102,849,443 | 2022-11-10 | Filing | |
| $3.91 | 8,600 | $33,635.46 | 98,849,443 | 2022-04-25 | Filing | |
| $3.83 | 31,685 | $121,318.70 | 98,840,843 | 2022-04-22 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $21.92 | 200,000 | $4,384,000.00 | 1,654,597 | 2026-01-12 | Filing | |
| $21.71 | 1,018,995 | $22,122,381.45 | 20,267,429 | 2025-12-31 | Filing | |
| $21.74 | 311,873 | $6,780,119.02 | 19,273,032 | 2025-12-29 | Filing | |
| $22.39 | 146,731 | $3,285,307.09 | 239,413 | 2025-12-23 | Filing | |
| $22.45 | 260,000 | $5,837,000.00 | 386,144 | 2025-12-23 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 6,937,112 | $150,535,330 | 0.21% | |
| 2. | 1,858,289 | $40,324,871 | 3.86% | |
| 3. | 525,863 | $11,411,227 | 0.04% | |
| 4. | 445,500 | $9,667,350 | 2.33% | |
| 5. | 276,530 | $6,000,701 | 0.52% |
News See All
15 Best Stocks Under $25 to Buy Now
Stock futures were marginally lower early December 29, as traders grabbed profits at record index levels and exited prominent technology names and precious metals following an explosive rally.
Roivant Sciences Ltd. (NASDAQ:ROIV) Q2 2026 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Roivant's Second Quarter 2025 Earnings Call. [Operator Instructions] Please note that today's conference is being recorded.
Do You Believe in the Growth Prospects of Roivant Sciences Ltd. (ROIV)?
Baron Funds, an investment management company, released its “Baron Health Care Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here.
13 Best Growth Stocks Under $25 to Buy Right Now
Recently, there have been concerns around the surge of fraudulent loans and private credit quality issues in the US.
Roivant's Brepocitinib Phase 3 Dermatomyositis Trial Hits Primary and All Key Secondary Endpoints
Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the best stocks to buy under $20.
10 Best Stocks to Buy Under $20
On September 16, Ali Dibadj, Janus Henderson Investors CEO, joined 'Squawk Box' on CNBC to discuss the latest market trends and suggest that small and mid-cap stocks have enormous potential to deliver...
Roivant Sciences (ROIV) Hits New All-Time High as Drug Candidate Clinical Trial Posts Impressive Results
This followed positive results from the phase 3 clinical trial of drug candidate Brepocitinib for the treatment of dermatomyositis (DM), where it saw significant and constant developments in as early ...
Roivant Sciences Ltd. (ROIV) Wins Orphan Drug Status in Japan for Mosliciguat
Roivant Sciences Ltd.
7 Hot Healthcare Stocks to Buy Right Now
The majority of Americans have experienced the annoyance of having their health insurance rejected, frequently without any recourse after contacting carriers by email and phone. Dr.